A Phase 2 interventional study of Pitolisant oral tablets and Placebo oral tablet in Prader-Willi Syndrome, sponsored by Harmony Biosciences Management, Inc.. Completed at 13 sites in United States. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 17th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2020, is one of 17 in phase 2, and was the 43rd registered.
144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.
Browse Prader-Willi Syndrome studies →9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 13–17
ConSynance Therapeutics · Sites in United States
Ages 13–50
Grace Kim · Sites in United States
Ages 18–26
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 6 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 16 · Phase 4 3
First in 1999; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 30 across 100 interventional studies indexed under Prader-Willi Syndrome.
Median enrollment 23 across the 58 interventional studies, 200 across the 11 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 69 have an industry lead sponsor. The 10 most frequent:
This study is registered under Harmony Biosciences Management, Inc., one of the names counted as Harmony Biosciences Holdings, Inc.. Under that name alone:
Harmony Biosciences Management, Inc. is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Harmony Biosciences Holdings, Inc. has 3 studies filed under Prader-Willi Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Prader-Willi Syndrome with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06366464Phase 3Harmony Biosciences Management, Inc.A Study of Pitolisant in Patients With Prader-Willi Syndrome | 2027-04 |
| NCT06144645Phase 3Foundation for Prader-Willi ResearchA Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS | 2027-04-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
| NCT07348601ConSynance TherapeuticsA Study of CSTI-500 in Patients With Prader-Willi Syndrome | 2027-06 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Prader-Willi Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi syndrome (PWS) ages 6 to 65 years.
The study will consist of a Screening Period, an 11-week Double-Blind Treatment Phase (including a 3-week Titration Period and an 8-week Stable Dose Period), and an optional Open Label Extension (OLE) Phase. The OLE Phase will be multi-year in duration and will continue until the Sponsor elects to terminate the study.
Approximately 60 patients ages 6 to 65 years who meet all eligibility criteria will be randomized at the Baseline Visit in a 1:1:1 ratio to lower dose pitolisant, higher dose pitolisant, or matching placebo. In the Double-Blind Treatment Phase, patients will be titrated to their randomized stable dose of study drug during the 3-week Titration Period.
After completion of the 3-week Titration Period, patients will continue to take study drug at their randomized stable dose once daily in the morning upon wakening for an additional 8 weeks of blinded treatment (Stable Dose Period). The duration of the Double-Blind Treatment Phase will be 11 weeks.
Following the 11-week Double-Blind Treatment Phase, eligible patients will be given the opportunity to participate in an optional OLE Phase. During the OLE Phase, all eligible patients will receive treatment with open-label pitolisant and will undergo titration during a 3-week Titration Period to a maximum target dose as specified in the protocol. At the end of the 3-week Titration Period, patients will continue to take their target dose of pitolisant once daily in the morning upon wakening until the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric patients (6 to less than 12 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning. Adolescent patients (12 to less than 18 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning. Adult patients (18 to 65 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.
Drug: Pitolisant oral tablets
Pediatric patients (6 to less than 12 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning. Adolescent patients (12 to less than 18 years of age): Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning. Adult patients (18 to 65 years of age): Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning.
Drug: Pitolisant oral tablets
Pediatric patients (6 to less than 12 years of age): Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets Adolescent patients (12 to less than 18 years of age): Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets Adult patients (18 to 65 years of age): Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets
Drug: Placebo oral tablet
Age-based dosing (prior to implementation of amendment 6) or weight-based dosing (after implementation of amendment 6)
Drug: Pitolisant oral tablets
Pitolisant 4.45 mg or 17.8 mg tablets
Matching placebo tablets
Excessive Daytime Sleepiness
Change in Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) (parent/caregiver version) score from Baseline to Week 11 for pitolisant compared with placebo. The score of the ESS-CHAD ranges from 0 to 24. A decrease in score represents an improvement in excessive daytime sleepiness.
Time frame: Baseline to Week 11
Excessive Daytime Sleepiness
Change in Caregiver Global Impression of Severity for Excessive Daytime Sleepiness. The Caregiver Global Impression of Severity for Excessive Daytime Sleepiness is a five-item scale that ranges from "not at all" to "very high likelihood." An assessment of being less likely to fall asleep represents an improvement in the caregiver's overall impression of the patient's excessive daytime sleepiness.
Time frame: Baseline to Week 11
Clinical Symptoms
Change in Clinical Global Impression of Severity of Overall Clinical Status. The Clinical Global Impression of Severity of Overall Clinical Status is a four-item scale that ranges from "normal" to "severely symptomatic." An assessment of less severe symptoms represents an improvement in the clinician's perception of the overall clinical status related to PWS.
Time frame: Baseline to Week 11
Behavior
Change in Aberrant Behavior Checklist, Second Edition. The Aberrant Behavior Checklist-Community, Second Edition, rates 58 specific symptoms on a four-item scale ranging from "not at all a problem" to "the problem is severe in degree." A decrease in score represents an improvement in the caregiver's impression in the patient's problematic behavior.
Time frame: Baseline to Week 11
Behavioral and Cognitive Rigidity
Change in Montefiore-Einstein Rigidity Scale - Prader-Willi Syndrome (MERS-R-PWS). The MERS-R-PWS is a clinician-rated, semi-structured interview conducted with both the patient with PWS and caregiver present. The MERS-R-PWS measures three domains of rigid behavior - behavior, cognitive, and protest. Within each domain, four items are rated on a scale ranging from 0 to 4. A decrease in score represents an improvement in rigid behavior.
Time frame: Baseline to Week 11
Psychomotor Function
Change in Cogstate Detection Test. The Cogstate Detection Test is a computerized test. Accuracy with a faster speed represents an improvement in psychomotor test performance.
Time frame: Baseline to Week 11
Attention
Change in Cogstate Identification Test. The Cogstate Identification Test is a computerized test. Accuracy with a faster speed represents an improvement in attention test performance.
Time frame: Baseline to Week 11
Working Memory
Change in Cogstate One Back Test. The Cogstate One Back Test is a computerized test. Accuracy with a faster speed represents a better working memory test performance.
Time frame: Baseline to Week 11
Caregiver Burden
Change in 22-Item Zarit Burden Interview. The Zarit Burden Interview is a self-reported questionnaire in which caregivers are asked to rate their experience on a five-item scale (0 = "never" and 4 = "nearly always") for 22 questions related to caregiver health and psychological well-being, finances, impact on social life, and relationship with the patient with PWS. A decrease in score represents an improvement in the caregiver's perceived burden.
Time frame: Baseline to Week 11
| Milestone | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo |
|---|---|---|---|
| Started | 20 | 22 | 23 |
| Completed | 18 | 21 | 20 |
| Not completed | 2 | 1 | 3 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Covid-19 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Change in Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) (parent/caregiver version) score from Baseline to Week 11 for pitolisant compared with placebo. The score of the ESS-CHAD ranges from 0 to 24. A decrease in score represents an improvement in excessive daytime sleepiness.
| score on a scale | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo |
|---|---|---|---|
| Excessive Daytime Sleepiness | -3.5 ± 1.14 | -5.0 ± 1.07 | -3.9 ± 1.08 |
Change in Caregiver Global Impression of Severity for Excessive Daytime Sleepiness. The Caregiver Global Impression of Severity for Excessive Daytime Sleepiness is a five-item scale that ranges from "not at all" to "very high likelihood." An assessment of being less likely to fall asleep represents an improvement in the caregiver's overall impression of the patient's excessive daytime sleepiness.
Results for this outcome have not been posted.
Change in Clinical Global Impression of Severity of Overall Clinical Status. The Clinical Global Impression of Severity of Overall Clinical Status is a four-item scale that ranges from "normal" to "severely symptomatic." An assessment of less severe symptoms represents an improvement in the clinician's perception of the overall clinical status related to PWS.
Results for this outcome have not been posted.
Change in Aberrant Behavior Checklist, Second Edition. The Aberrant Behavior Checklist-Community, Second Edition, rates 58 specific symptoms on a four-item scale ranging from "not at all a problem" to "the problem is severe in degree." A decrease in score represents an improvement in the caregiver's impression in the patient's problematic behavior.
Results for this outcome have not been posted.
Change in Montefiore-Einstein Rigidity Scale - Prader-Willi Syndrome (MERS-R-PWS). The MERS-R-PWS is a clinician-rated, semi-structured interview conducted with both the patient with PWS and caregiver present. The MERS-R-PWS measures three domains of rigid behavior - behavior, cognitive, and protest. Within each domain, four items are rated on a scale ranging from 0 to 4. A decrease in score represents an improvement in rigid behavior.
Results for this outcome have not been posted.
Change in Cogstate Detection Test. The Cogstate Detection Test is a computerized test. Accuracy with a faster speed represents an improvement in psychomotor test performance.
Results for this outcome have not been posted.
Change in Cogstate Identification Test. The Cogstate Identification Test is a computerized test. Accuracy with a faster speed represents an improvement in attention test performance.
Results for this outcome have not been posted.
Change in Cogstate One Back Test. The Cogstate One Back Test is a computerized test. Accuracy with a faster speed represents a better working memory test performance.
Results for this outcome have not been posted.
Change in 22-Item Zarit Burden Interview. The Zarit Burden Interview is a self-reported questionnaire in which caregivers are asked to rate their experience on a five-item scale (0 = "never" and 4 = "nearly always") for 22 questions related to caregiver health and psychological well-being, finances, impact on social life, and relationship with the patient with PWS. A decrease in score represents an improvement in the caregiver's perceived burden.
Results for this outcome have not been posted.
Collected over Data are presented for adverse events occurring after first dose of study drug and up to 30 days after the date of last dose of study drug, for a total of up to 15 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Treatment Phase Lower Dose Pitolisant | 0/20 (0%) | 0/20 (0%) | 13/20 (65%) |
| Double-Blind Treatment Phase Higher Dose Pitolisant | 0/22 (0%) | 0/22 (0%) | 8/22 (36.4%) |
| Double-Blind Treatment Phase Placebo | 0/23 (0%) | 1/23 (4.3%) | 9/23 (39.1%) |
| Event | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo |
|---|---|---|---|
| Deep vein thrombosisVascular disorders | 0/20 | 0/22 | 1/23 |
| Event | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo |
|---|---|---|---|
| AnxietyPsychiatric disorders | 4/20 | 1/22 | 2/23 |
| IrritabilityPsychiatric disorders | 4/20 | 1/22 | 1/23 |
| HeadacheNervous system disorders | 3/20 | 2/22 | 2/23 |
| COVID-19Infections and infestations | 0/20 | 3/22 | 2/23 |
| Sleep disorderPsychiatric disorders | 2/20 | 0/22 | 0/23 |
| NasopharyngitisInfections and infestations | 2/20 | 2/22 | 1/23 |
| Abdominal pain upperGastrointestinal disorders | 2/20 | 0/22 | 0/23 |
| HyperphagiaMetabolism and nutrition disorders | 2/20 | 1/22 | 2/23 |
| Age, Continuous(years) | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo | Total |
|---|---|---|---|---|
| Mean | 12.1 ± 5.44 | 13.1 ± 6.70 | 11.9 ± 4.31 | 12.4 ± 5.50 |
| Sex: Female, Male(Participants) | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo | Total |
|---|---|---|---|---|
| Female | 11 | 12 | 9 | 32 |
| Male | 9 | 10 | 14 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 4 |
| Not Hispanic or Latino | 20 | 20 | 21 | 61 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo | Total |
|---|---|---|---|---|
| United States | 20 | 22 | 23 | 65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Aug 2022, 20 months.
Results were first posted in Oct 2025, 3 years 2 months after primary completion. A results delay was requested in Jul 2023.
Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitolisant
Harmony Biosciences Management, Inc. →